SLAMF7 FPBMC / University of Virginia - LARVOL DELTA

MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: University of Virginia

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • SLAMF7

MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: University of Virginia | N=18 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Hematological Malignancies • Multiple Myeloma • Oncology • SLAMF7

MM FPBMC: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: University of Virginia | Trial completion date: Jan 2030 ➔ May 2030 | Trial primary completion date: Jan 2027 ➔ May 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • IFNG • SLAMF7 • SOX2

MM BATs: Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: University of Virginia | Not yet recruiting ➔ Recruiting | Phase classification: P1 ➔ P1/2 | Trial completion date: Jun 2028 ➔ Jan 2030 | Trial primary completion date: Jun 2027 ➔ Jan 2027

Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • IFNG • SLAMF7 • SOX2

MM BATs: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: University of Virginia | Trial completion date: Jan 2027 ➔ Jun 2028 | Trial primary completion date: Jan 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • IFNG • SLAMF7

MM BATs: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=25; Not yet recruiting; Sponsor: University of Virginia

Clinical • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology • IFNG